MAGED1

Across TCGA pan-cancer cohorts, MAGED1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAGED1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAGED1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MAGED1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, OV, and CHOL are the cancer types where MAGED1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.978	0.609	<.001	26	view →
OV	OS	Median	II,III,IV	0.511	0.844	<.001	24	view →
CHOL	DFS	Median	All	0.074	0.447	.010	18	view →
ESCA	OS	Median	All	0.198	0.872	.003	12	view →
TGCT	DFS	Median	All	0.094	0.801	.008	6	view →
LUSC	OS	Median	All	0.173	0.724	.046	3	view →
SKCM	OS	Median	All	0.686	0.329	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAGED1–UCEC (DFS)

Open the UCEC breakdown →